Blood Transfusion Thresholds in Cancer Patients Undergoing Chemotherapy

Immediate Transfusion Indications

The European Society for Medical Oncology (ESMO) guidelines recommend that blood transfusions should be administered to cancer patients undergoing chemotherapy when hemoglobin falls below 7-8 g/dL or when severe anemia-related symptoms occur at any hemoglobin level, regardless of the absolute value 1, 2, 3
Transfuse without delay when hemoglobin is less than 7-8 g/dL with or without symptoms, as recommended by the ESMO guidelines 1, 2, 4
Severe anemia-related symptoms at any hemoglobin level, including tachycardia, tachypnea or dyspnea, and severe fatigue limiting activities of daily living, require immediate transfusion as per the ESMO guidelines 1, 2, 3

The National Comprehensive Cancer Network (NCCN) guidelines state that transfusion is rarely indicated when hemoglobin is greater than 10 g/dL 5, 6
A restrictive transfusion strategy (7-9 g/dL target) has shown no mortality differences compared to liberal strategies (10-12 g/dL) in critically ill patients, according to the NCCN guidelines 5, 6

The ESMO guidelines emphasize that symptom assessment is mandatory before transfusion decisions, and hemoglobin level alone should not dictate transfusion 1, 2, 3
Evaluate for signs of tissue hypoxia including dyspnea, fatigue, tachycardia, and functional impairment before making transfusion decisions, as recommended by the ESMO guidelines 1, 2

The NCCN guidelines recommend administering single units in hemodynamically stable patients and reassessing after each unit with post-transfusion hemoglobin measurement 3, 5, 6
Premedication (acetaminophen or antihistamine) is seldom required unless long-term transfusions are planned, according to the NCCN guidelines 5, 6

The American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) guidelines state that ESAs may be considered instead of transfusion in specific circumstances, such as non-curative chemotherapy with hemoglobin less than 10 g/dL 7, 8
Do not use ESAs in curative-intent chemotherapy, as recommended by the ASCO and ASH guidelines 7, 8

The ESMO guidelines recommend evaluating for absolute iron deficiency (ferritin less than 100 ng/mL) and functional iron deficiency (transferrin saturation less than 20% with ferritin greater than 100 ng/mL) before any anemia treatment 1, 2, 4
Correct iron deficiency with IV iron before or during ESA therapy if ESAs are used, as recommended by the ESMO guidelines 1, 2, 4

The NCCN guidelines state that transfusion carries significant risks, including increased venous thromboembolism (OR 1.60), increased arterial thromboembolism (OR 1.53), and increased mortality (OR 1.34) 5, 6, 3
Febrile non-hemolytic reactions and circulatory overload and pulmonary edema with rapid transfusion are also potential risks of transfusion, according to the NCCN guidelines 5, 6, 3

The ESMO guidelines recommend avoiding transfusion based solely on hemoglobin threshold without assessing clinical symptoms and tissue hypoxia 3
Do not overlook volume status as hemodilution can cause falsely low hemoglobin values, and do not use transfusion as definitive therapy, as recommended by the ESMO guidelines 3
Avoid using liberal transfusion strategies (targeting hemoglobin 10-12 g/dL) as they increase risks without demonstrated benefit, according to the NCCN guidelines 5, 6